October 7, 2025 — Leads & Copy — Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) has announced a lead order of $330,000 for a non-brokered private placement of up to $700,000, according to a recent press release.
Purchasers can subscribe for Units at $0.11, each consisting of one Common Share and one Warrant. Each Warrant allows the holder to acquire one Common Share at $0.15 for two years from the Closing Date, subject to an accelerator clause.
A Director of the Company is participating in the Offering, constituting a related party transaction under Multilateral Instrument 61-101, but the Company is relying on exemptions from formal valuation and minority shareholder approval requirements.
The proceeds will support general working capital, including marketing and sales of VesCell™.
Hemostemix, founded in 2003, is an autologous stem cell therapy platform company. Its VesCell™ (ACP-01) therapy has completed seven clinical studies and shown statistically significant results for treating various conditions.
Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@hemostemix.com / PH: 905-580-4170
Source: Hemostemix
